Abstracts tagged "cardiovascular disease and nonsteroidal antiinflammatory drugs (NSAIDs)"

Abstract Number: 578 • 2014 ACR/ARHP Annual Meeting
Female Patients but Not Male Patients with Ankylosing Spondylitis Are at Increased Risk of Developing Ischemic Heart Disease: A Population-Based Cohort Study
Ivette Essers^1,2, Carmen Stolwijk^1,2, Annelies Boonen^3,4, Marie L. De Bruin⁵, Marloes Bazelier⁵, Frank de Vries^5,6,7,8 and Astrid Van Tubergen^1,2, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands, ⁶Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Southampton, United Kingdom, ⁸Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands
Background/Purpose: It is well recognized that rheumatoid arthritis is an independent risk factor for cardiovascular disease. For ankylosing spondylitis (AS), the literature on this risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].